Eighteen patients with 21 serious infections were treated with ceftriaxone, 1 g intravenously every 12 h, for a mean duration of 8 days. Eighteen gram-negative and two gram-positive organisms were isolated. Sites of infection included blood (three patients), urinary tract (six patients), respiratory tract (seven patients), biliary tract (three patients), ascitic fluid (one patient), and skin (one patient). Serum, bile, and ascitic fluid concentrations of ceftriaxone were in excess of the minimal bactericidal concentration required for the infecting organism in all cases. A bacteriological response was demonstrated in 94% of the infections. A clinical response occurred in four infections from which no pathogens were recovered. In one patient, ceftriaxone failed to eradicate a peritoneal infection due to Bacteroides fragilis. In two patients, superinfection with enterococci developed both during and after therapy. Systemic tolerance to ceftriaxone was excellent.
cies, and non-enterococcal streptococci (1, 3, 5, 9, 11) . Pharmacokinetic data from humans show that ceftriaxone, as compared with other cephalosporins, has an unusually long half-life of 6 806, 1981) , allowing extension of the dosage interval to 12 h. This report details the results of therapy with ceftriaxone, administered every 12 h, in 18 patients with acute bacterial infections.
MATERIALS AND METHODS
Eighteen males, 53 to 80 years of age, were treated with ceftriaxone for suspected or documepted acute bacterial infections. Most of these patients had underlying diseases such as diabetes, cirrhosis, atherosclerotic heart disease, chronic obstructive pulmonary disease, and malignant disease. Ceftriaxone was administered as a 30-min intravenous infusion at a dose of 1 g every 12 h for a mean duration of 8 days (range, 3 to 14 days). One patient (patient 15) with pneumonia caused by two gram-negative organisms received a larger dose (2 g every 12 h) because of overwhelming disease.
Patients with bacteremia had at least one positive blood culture in association with chills and fever. Those with pneumonia had radiographic infiltrates and both leukocytes and bacteria on Gram stains of deepsuctioned sputum. Urinary tract infection was defined by the presence of >105 organisms per ml of urine with associated pyuria. Cirrhotic patients with peritonitis had ascitic fluid leukocytosis (>300 leukocytes per ml) and a positive culture from this fluid. Cholecystitis was defined as right upper quadrant pain in association with fever, leukocytosis, and cholelithiasis, as demonstrated by ultrasound, radioisotope scan, or endoscopy. The diagnosis of skin infection was based on local suppuration, induration, a positive Gram stain of the exudate, and a positive culture.
Appropriate cultures were obtained before therapy, 48 h after therapy was begun, and after treatment was completed. Additional cultures were obtained 4 to 6 weeks after treatment from patients with urinary tract infections. Bacteriological response was defined as elimination of the initial pathogen within 48 h after therapy was begun and for the duration of the followup period. Bacteriological improvement was defined as eradication of the pretreatment pathogen, with subsequent appearance of one or more new pathogenic species susceptible to ceftriaxone. Persistence of the initial pathogen after 48 h of therapy was considered to indicate bacteriological failure. Clinical response was defined as complete resolution of abnormal findings. Clinical improvement was defined as incomplete resolution of abnormal findings or as a relapse during the follow-up period. No apparent response to therapy was considered to indicate clinical failure.
Complete blood count, platelet count, serum electrolytes, blood urea nitrogen, creatinine, serum biirubin, alkaline phosphatase, glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, and prothrombin and partial thromboplastin times were obtained before, during, and after therapy.
Specimens were processed routinely in the bacteriology laboratory of the Veteran's Hospital and identified by standard techniques. Susceptibility of isolated pathogens to ceftriaxone was determined by the disk method of Bauer et al. (2) and by the broth dilution method. An 18-h culture of the organism grown in Mueller-Hinton broth was diluted to a final concentration of 105 organisms per ml, and 0.5-ml amounts were inoculated into serial twofold dilutions of ceftriaxone to give a final volume of 1.0 ml. The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antibiotic preventing visible turbidity. The minimal bactericidal concentration (MBC) was defined as the lowest concentration of antibiotic resulting in no bacterial growth after a subculture of 0.01 ml onto antibiotic-free Mueller-Hinton agar.
Blood specimens were obtained 1 and 12 h after an infusion of ceftriaxone on days 1 and 4 of the study.
Serum specimens were frozen at -20°C. Antibiotic assays were performed within 2 weeks by using a modified agar well diffusion technique in MuellerHinton agar, with Escherichia coli 1346 as the standard.
RESULTS
Microbiology. Among 20 organisms isolated, 18 were gram negative, and 2 were gram positive. Sites of infection included blood (three patients), urinary tract (six patients), respiratory tract (seven patients), biliary tract (three patients), ascitic fluid (one patient) and skin (one patient). The same E. coli biotype was isolated from both the bile and the blood of patient 1 (iii) Respiratory infection. Six patients had pneumonia, and one patient had purulent tracheobronchitis. Sputum was obtained from four patients by nasotracheal suctioning, and expectorated sputum was evaluated in the remaining three patients. Species of known virulence were considered invasive if they predominated in purulent specimens and if correlation existed between Gram stain and clinical findings. Pathogens were recovered from five patients, all of whom showed a bacteriological response. Patient 15 died of hepatic failure after a bacteriological response was demonstrated. The remaining two patients had infiltrates, fever, leukocytosis, and organisms seen on Gram stain (gram-positive diplococci in patient 10 and gram-negative coccobacilli in patient 16); however, only normal flora were isolated from sputum cultures. Both patients showed clinical and radiographic resolution of their infections.
(iv) Bilary tract infection. Three patients had acute cholecystitis, and all were cured by surgery and ceftriaxone. Patient 1 had a perforated gallbladder, and E. coli was isolated from both bile and blood. Sterilization of bile was documented 2 days after surgery. The bile concentration of ceftriaxone 14 h after discontinuation of therapy was 13.5 ,ug/ml. Patient 18 had E. coli bacteremia and underwent surgery on day 9 of ceftriaxone therapy. The concentration of ceftriaxone in the bile was 1,600 ,ug/ml 5 h after a dose, and cultures were sterile. Patient 8 had right upper quadrant pain, fever, leukocytosis, and an abnormal ultrasound examination. Cholecystectomy was performed on day 2 of antibiotic therapy, at which time bile cultures were sterile. There was a fall in temperature and peripheral leukocyte count after institution of ceftriaxone treatment and before surgery was carried out.
(v) Skin infection. Patient 13 was treated with ceftriaxone for an infected diabetic foot ulcer with cellulitis. S. marcescens was isolated from the ulcer, and P. mirabilis was recovered from the blood. The patient ultimately required amputation, after a bacteriological response was demonstrated.
(vi) Peritoneal infection. Patient 14, with portal hypertension and ascites, developed E. coli peritonitis. Paracentesis after 2 days of therapy with ceftriaxone yielded no E. coli growth, but infection with B. fragilis and C. albicans was documented. A small-bowel perforation was found during surgery, and treatment was changed to clindamycin, ampicillin, amikacin, and amphotericin B. The patient died of septic shock, hepatic failure, and C. albicans peritonitis. Ceftriaxone concentrations in serum and other body fluids. Ceftriaxone serum concentrations were determined on days 1 and 4 of therapy (Table 1) . Concentrations in bile and ascitic fluid were also measured. Serum concentrations 1 h after a dose were 20 to 150 jig/ml (mean, 68.4 ,ug/ ml) on day 1 of treatment and 50 to 180 ,ug/ml (mean, 120.2 ,ug/ml) on day 4 of treatment. Trough concentrations were <6 to 100 ,ug/ml (mean, 37.8 jig/ml) on day 1 of treatment and <6 to 100 ,ug/ml (mean, 48.7 p.g/ml) on day 4 of treatment. The highest trough concentration (100 ,ug/ml) was obtained from a patient with moderate renal insufficiency (creatinine, 4.3 mg/ 100 ml).
The ascitic fluid concentration of ceftriaxone in a patient with peritonitis was 16 ,ug/ml 1 h after a dose. Bile concentrations of ceftriaxone were measured in two patients. In patient 1, aspiration of bile from the T-tube 14 h after the final dose yielded a concentration of 13.5 ,ug/ml. Patient 18 had a bile concentration of 1,600 ,ug/ ml 5 h after a dose of 1 g on day 9 of therapy.
Superinfection. Two patients developed infections due to enterococci during or after ceftriaxone therapy. Patient 12 required a cystotomy and permanent catheter drainage for treatment of urethral strictures, and an enterococcal infection developed on day 5 of therapy. Patient 4 was successfully treated for a mixed E. coli and P. mirabilis urinary tract infection. Three days after completion of therapy, enterococci were cultured from the urine at a time when the patient was asymptomatic.
Toxicity. Local tolerance to intravenous injection was excellent. Transient neutropenia was noted in one patient (patient 2) whose leukocyte count decreased to 3,100/mm3 after 7 days of therapy. One day after ceftriaxone therapy was discontinued, the leukocyte count was 6,500/ mm3. Patient 9 developed fever after 7 days of treatment. After ceftriaxone therapy was discontinued, the serum alkaline phosphatase and transaminase levels became elevated. Quinidine therapy was then discontinued, and both fever and hepatic abnormalities resolved. DISCUSSION Pharmacokinetic studies (7, 8) have demonstrated that the half-life of ceftriaxone is approximately 6 to 8 h. This unusually long half-life is attributed to a significant nonrenal mechanism of excretion and distribution, presumably hepatobiliary. With a dose of 1 g every 12 h, serum, biliary, and ascitic fluid concentrations of ceftriaxone were significantly in excess of the MICs and MBCs of this antibiotic for individual isolates.
Ceftriaxone has a broad spectrum of activity, especially against the Enterobacteriaceae and non-enterococcal streptococci. It has greater in vitro activity against non-enterococcal streptococci (particularly Streptococcus pneumoniae) than moxalactam (1, 6, 9, 10) and greater activity against all Proteus species than either cefotaxime or moxalactam (4, 9 Hinkle and Bodey (5) showed that 98% of their penicillin-resistant Staphylococcus aureus species were inhibited by 6 .25 ,ug of ceftriaxone per ml. Other investigators (11) have shown ceftriaxone to be comparable to cefotaxime against this organism and superior to moxalactam. Only one patient in this study was infected with S. aureus. Although the MIC of ceftriaxone for this organism was 12.5 ,ug/ml, serum concentrations several times greater than the MIC were achieved. The patient showed complete bacteriological and clinical responses within 1 week.
In summary, this study suggests that ceftriaxone is an effective and safe cephalosporin for the treatment of urinary, respiratory, and biliary tract infections and bacteremia not due to endocarditis. Because of its long half-life and increased potency against certain pathogens, it can be administered in a lower dose and at longer intervals than currently available cephalosporins.
